DNM1L and hepatocellular carcinoma: P110 has been reported as a Drp1-specific inhibitor to impede mitochondrial fragmentation by inhibiting Drp1 enzyme activity as well as blocking Drp1/Fis1 interaction.59 Accordingly, based on our finding, compared to mdivi-1, P110 combination with Met inhibitor may be a more individualized and potential therapy to prevent metastasis in HCC patients.